<DOC>
	<DOC>NCT00190983</DOC>
	<brief_summary>This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.</brief_summary>
	<brief_title>A Trial for Patients With Advanced/Recurrent Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma in Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms, Female</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Recurrent squamous or nonsquamous cell carcinoma of the cervix with documented disease progression Measurable disease Gynecologic Oncology Group (GOG) performance status 02 Patients must have received one prior systemic chemotherapy for persistent or recurrent disease Patients with mild to moderate renal insufficiency should avoid taking nonsteroidal antiinflammatory drugs (NSAIDs_ with short elimination halflives for a period of 2 days before, the day of, and 2 days following administration of pemetrexed. All patients taking NSAIDs with longer halflives, should interrupt dosing for at least 5 days before, the day of, and 2 days following pemetrexed administration. Folic Acid (3501000 ug) must be given daily beginning approximately 57 days prior to first does of pemetrexed and continuing daily until 3 weeks after the last dose of study therapy. Vitamin B12 (1000 ug) will be administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy Prior Pemetrexed Patients who have received radiation to more than 25% of marrow bearing areas Any evidence of other malignancy within last 5 years, with exception of nonmelanoma skin cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>